Story · Medicine & Biotech

Liporaxel, Yescarta advance in Korean coverage review; Tevimbra falls short in SCLC

1 outlet · first reported by Korea Biomedical Review on

Daehwa Pharmaceutical’s oral cancer drug Liporaxel and Gilead Sciences Korea’s CAR-T therapy Yescarta cleared an initial hurdle toward expanded insurance coverage in Korea, while BeOne Medicines Korea’s Tevimbra failed to advance for extensive-stage small cell lung cancer (SCLC).The Health Insurance (Korea Biomedical Review)

Coverage, in order

  1. Korea Biomedical Review South Korea obscure review
    Liporaxel, Yescarta advance in Korean coverage review; Tevimbra falls short in SCLC

    Daehwa Pharmaceutical’s oral cancer drug Liporaxel and Gilead Sciences Korea’s CAR-T therapy Yescarta cleared an initial hurdle toward expanded insurance coverage in Korea, while BeOne Medicines Korea’s Tevimbra failed to advance for extensive-stage small cell lung cancer (SCLC).The Health Insurance

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.